The Precision Cancer Diagnostic Test Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Advancements in Technologies such as Functional Precision Medicine (FPM) Models
Some of the practical challenges of FPM can be addressed using new technologies created at the intersection of engineering and biology. Technology targeted at simulating the tumour microenvironment, particularly the extracellular matrix, has made significant progress. Organ chips (sometimes referred to as tissue chips or microphysiological systems) are indeed being used to depict cancer inside the tumour microenvironment. Such microfluidics devices, which are typically composed of tissue-specific types of cells, extracellular matrix gels, and cancerous cells, attempt to replicate the molecular and mechanical signals present in human tissue. One of the possible advantages of organ chips is their ability to replicate medicine distribution, pharmacokinetics, pharmacodynamics, and drug toxicity.
Some of the hurdles to the broad use of organ chips in FPM include low drug testing throughput and the necessity for specialised skills to create and operate these devices. Allowing cells to remain in their native habitat throughout pharmaceutical therapy is another way to simulate tumour settings. This comprises medication treatment on individual tumour sections or fine-needle biopsies, wherein immunofluorescent cell death signs can be used to assess drug sensitivity. Its use of drug-containing microdevices which may be implanted directly into patients' tumours is another promising approach for FPM. The medications in such microdevices can affect surrounding tissues, and therapy results in tumours can indeed be evaluated after they've been removed.
What Questions Should You Ask before Buying a Market Research Report?
• How is the precision cancer diagnostic test market evolving?
• What is driving and restraining the precision cancer diagnostic test market?
• How will each precision cancer diagnostic test submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each precision cancer diagnostic test submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading precision cancer diagnostic test markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the precision cancer diagnostic test projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implication of precision cancer diagnostic test projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the precision cancer diagnostic test market?
• Where is the precision cancer diagnostic test market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the precision cancer diagnostic test market today, and over the next 10 years:
• Our 602-page report provides 347 tables and 326 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analyse of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the precision cancer diagnostic test market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising precision cancer diagnostic test prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in this report
Biopsy Method
• Tissue Biopsy
• Liquid Biopsy
End-User
• Hospitals
• Clinics
• Research Institutes
Category
• Cancer Imaging
• Molecular Cancer Testing
• Tumour Marker Immunoassays
• POC Colon Cancer Tests
• Other Categories
Cancer Type
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Pancreatic Cancer
• Other Cancer Type
Cancer Testing
• Blood-Based Molecular Cancer Tests
• HPV Genotyping
• Circulating Tumour Cell (CTC) Tests
• Next-Generation Sequencing Tests
Imaging Test
• Computed Tomography
• Magnetic Resonance Imaging
• Digital & Analog Mammography
• Positron Emission Tomography
• Digital Breast Tomosynthesis
• Molecular Breast Imaging
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
North America
• U.S.
• Canada
• Mexico
Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of Latin America, Middle East and Africa
The report also includes profiles and for some of the leading companies in the Precision Cancer Diagnostic Test Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Abbott Laboratories (Abbott)
• Agilent Technologies, Inc.
• AstraZeneca PLC (AstraZeneca)
• Becton, Dickinson and Firm (BD)
• Biocept, Inc.
• Bio-Rad Laboratories Inc.
• Epigenomics AG
• Illumina, Inc. (Illumina)
• Myriad Genetics, Inc. (Myriad)
• Quest Diagnostics Incorporated
Overall world revenue for Precision Cancer Diagnostic Test Market, 2022 to 2032 in terms of value the market will surpass US$15,834 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Precision Cancer Diagnostic Test Market, 2022 to 2032 Market report help you?
In summary, our 602-page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Precision Cancer Diagnostic Test Market, 2022 to 2032 Market, with forecasts for biopsy method, end-user, cancer type, category, molecular cancer testing each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for four regional and 20 key national markets – See forecasts for the Precision Cancer Diagnostic Test Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Precision Cancer Diagnostic Test Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analysis for the Precision Cancer Diagnostic Test Market, 2022 to 2032 and leading companies. You will find data, trends and predictions.
'
1 Report Overview
1.1 Introduction to Precision Cancer Diagnostic Test Market
1.2 Global Precision Cancer Diagnostic Test Market Overview
1.3 What Are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Precision Cancer Diagnostic Test Market Definition
1.6 Why You Should Read this Report
1.7 What this Report Delivers
1.8 Key Questions Answered by this Analytical Report Include:
1.9 Who is this Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Reports
1.13 About
2 Executive Summary
3 Global Market Dynamics
3.1 Market Driving Factors
3.1.1 Emerging FPM Models and Technologies
3.1.2 NGS Technologies Are Rapidly Being Used in Place of Traditional Approaches
3.1.3 Precision Cancer Medicine's Expanding Breadth
3.2 Market Restraining Factors
3.2.1 Disadvantages and Limitations of Precision Medicine in Cancer
3.2.2 Cost of Cancer Precision Medicine
3.2.3 Difficulty of Converting Basic Genetic Data into Clinically Relevant and Effective Conclusions
3.3 Opportunities in the Global Market
3.3.1 Enhanced Trial Opportunities
3.3.2 Number of Companion Molecular Diagnostic Assays Approved by the FDA is Increasing
3.3.3 Integration of Diagnostic and Treatment Data with Emerging Artificial Intelligence/Machine Learning Platforms
3.3.4 CDx Can Play an Important Function
3.4 Challenges in the Global Market
3.4.1 Expense of Testing for Genetic Changes and Subsequent Targeted Therapy
3.4.2 Precision Medicine's Incorporation into Clinical Oncology Operations Has Been Delayed
3.4.3 Technical Difficulties Related with the Development of Precision Medicine’s Evidence
3.5 SWOT Analysis
3.6 PEST Analysis
3.6.1 Political
3.6.2 Economical
3.6.3 Social
3.6.4 Technological
3.7 Porters Analysis
3.7.1 Competitive Rivalry
3.7.2 Bargaining Power of Suppliers
3.7.3 Bargaining Power of Customers
3.7.4 Threat of New Entrants
3.7.5 Threat of Substitutes
4 Global Precision Cancer Diagnostic Test Market Analysis
4.1 Global Market Outlook
4.2 Global Market Size Estimation and Forecast
4.2.1 Pre-COVID-19 Market Scenario
4.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
5 Global Precision Cancer Diagnostic Test Market Analysis by Region
5.1 North America
5.2 Europe
5.3 Asia-Pacific
5.4 LAMEA
5.5 Regional Market Size Estimation and Forecast
5.5.1 Pre-COVID-19 Market Scenario
5.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Market Size Estimation and Forecast by Biopsy Method
6.1 Tissue Biopsy
6.2 Liquid Biopsy
6.3 Pre-COVID-19 Market Scenario
6.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Market Size Estimation and Forecast by End-User
7.1 Hospitals
7.2 Clinics
7.3 Research Institutes
7.4 Pre-COVID-19 Market Scenario
7.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Market Size Estimation and Forecast by Category
8.1 Cancer Imaging
8.2 Molecular Cancer Testing
8.3 Tumour Marker Immunoassays
8.4 POC Colon Cancer Tests
8.5 Others
8.6 Pre-COVID-19 Market Scenario
8.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Market Size Estimation and Forecast by Cancer Type
9.1 Breast Cancer
9.2 Lung Cancer
9.3 Colorectal Cancer
9.4 Melanoma
9.5 Pancreatic Cancer
9.6 Other Cancer Types
9.7 Pre-COVID-19 Market Scenario
9.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Market Size Estimation and Forecast by Molecular Cancer Testing
10.1 Blood-Based Molecular Cancer Tests
10.2 HPV Genotyping
10.3 Circulating Tumour Cell (CTC) Tests
10.4 Next-Generation Sequencing Tests
10.5 Pre-COVID-19 Market Scenario
10.6 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Market Size Estimation and Forecast by Cancer Imaging Test
11.1 Computed Tomography
11.2 Magnetic Resonance Imaging
11.3 Digital & Analog Mammography
11.4 Positron Emission Tomography
11.5 Digital Breast Tomosynthesis
11.6 Molecular Breast Imaging
11.7 Pre-COVID-19 Market Scenario
11.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 North America Market Size Estimation and Forecast
12.1 Market Outlook
12.2 North America Market Size Estimation and Forecast
12.2.1 Pre-COVID-19 Market Scenario
12.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.3 Country Market Size Estimation and Forecast
12.3.1 Pre-COVID-19 Market Scenario
12.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.4 North America Market Size Estimation and Forecast by Biopsy Method
12.4.1 Pre-COVID-19 Market Scenario
12.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.5 North America Market Size Estimation and Forecast by End-User
12.5.1 Pre-COVID-19 Market Scenario
12.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.6 North America Market Size Estimation and Forecast by Category
12.6.1 Pre-COVID-19 Market Scenario
12.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.7 North America Market Size Estimation and Forecast by Cancer Type
12.7.1 Pre-COVID-19 Market Scenario
12.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.8 North America Market Size Estimation and Forecast by Molecular Cancer Testing
12.8.1 Pre-COVID-19 Market Scenario
12.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.9 North America Market Size Estimation and Forecast by Cancer Imaging Test
12.9.1 Pre-COVID-19 Market Scenario
12.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.10 US Precision Cancer Diagnostic Test Market Analysis
12.10.1 Increasing Number of Precision Medicine Clinical Trials in the United States
12.10.2 Pre-COVID-19 Market Scenario
12.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.11 Canada Precision Cancer Diagnostic Test Market Analysis
12.11.1 Adoption of New Systemic Cancer Medicines in Canada is a Multi-Step Process
12.11.2 The Use of Precision Medicine in Canada Will Aid in the Control of Cancer
12.11.3 Pre-COVID-19 Market Scenario
12.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12.12 Mexico Precision Cancer Diagnostic Test Market Analysis
12.12.1 Developing Successful and Long-Term Precision Oncology Programmes in Mexico in Collaboration with Government Authorities and Institutions
12.12.2 Pre-COVID-19 Market Scenario
12.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Europe Market Size Estimation and Forecast
13.1 Market Outlook
13.2 Europe Market Size Estimation and Forecast
13.2.1 Pre-COVID-19 Market Scenario
13.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.3 Country Market Size Estimation and Forecast
13.3.1 Pre-COVID-19 Market Scenario
13.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.4 Europe Market Size Estimation and Forecast by Biopsy Method
13.4.1 Pre-COVID-19 Market Scenario
13.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.5 Europe Market Size Estimation and Forecast by End-User
13.5.1 Pre-COVID-19 Market Scenario
13.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.6 Europe Market Size Estimation and Forecast by Category
13.6.1 Pre-COVID-19 Market Scenario
13.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.7 Europe Market Size Estimation and Forecast by Cancer Type
13.7.1 Pre-COVID-19 Market Scenario
13.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.8 Europe Market Size Estimation and Forecast by Molecular Cancer Testing
13.8.1 Pre-COVID-19 Market Scenario
13.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.9 Europe Market Size Estimation and Forecast by Cancer Imaging Test
13.9.1 Pre-COVID-19 Market Scenario
13.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.10 Germany Precision Cancer Diagnostic Test Market Analysis
13.10.1 Rapid Integration of Interdisciplinary Techniques in Germany
13.10.2 Pre-COVID-19 Market Scenario
13.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.11 UK Precision Cancer Diagnostic Test Market Analysis
13.11.1 Expanding Clinical Trails Studies in UK
13.11.2 Investment in Pancreatic Cancer Research
13.11.3 Pre-COVID-19 Market Scenario
13.11.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.12 France Precision Cancer Diagnostic Test Market Analysis
13.12.1 Pre-COVID-19 Market Scenario
13.12.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.13 Italy Precision Cancer Diagnostic Test Market Analysis
13.13.1 The Expansion of Precision Oncology in Italy Has Been Impeded by a Lack of Guidelines
13.13.2 Pre-COVID-19 Market Scenario
13.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.14 Spain Precision Cancer Diagnostic Test Market Analysis
13.14.1 Precision Cancer Diagnostic Test Research is Now Focusing on Detecting a Far Larger Number of Mutations in Spain
13.14.2 Pre-COVID-19 Market Scenario
13.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13.15 Rest of Europe Precision Cancer Diagnostic Test Market Analysis
13.15.1 Pre-COVID-19 Market Scenario
13.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 Asia-Pacific Market Size Estimation and Forecast
14.1 Market Outlook
14.2 Asia-Pacific Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Country Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 Asia-Pacific Market Size Estimation and Forecast by Biopsy Method
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 Asia-Pacific Market Size Estimation and Forecast by End-User
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 Asia-Pacific Market Size Estimation and Forecast by Category
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 Asia-Pacific Market Size Estimation and Forecast by Cancer Type
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 Asia-Pacific Market Size Estimation and Forecast by Molecular Cancer Testing
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 Asia-Pacific Market Size Estimation and Forecast by Cancer Imaging Test
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 China Precision Cancer Diagnostic Test Market Analysis
14.10.1 Large-Scale Deployment of Self-Powered Triboelectric Nanogenerator (TENG) Devices Has Promise for Cancer Treatment
14.10.2 Pre-COVID-19 Market Scenario
14.10.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 India Precision Cancer Diagnostic Test Market Analysis
14.11.1 Pre-COVID-19 Market Scenario
14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 Japan Precision Cancer Diagnostic Test Market Analysis
14.12.1 Precision Oncology Is Revolutionising Cancer Patient Treatment in Japan, but Many Hospitals Are Having Trouble Putting it into Practise
14.12.2 Pre-COVID-19 Market Scenario
14.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 South Korea Precision Cancer Diagnostic Test Market Analysis
14.13.1 Various Precision Medicine Collaborations Are Taking Place in South Korea
14.13.2 Pre-COVID-19 Market Scenario
14.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.14 Australia Precision Cancer Diagnostic Test Market Analysis
14.14.1 Pre-COVID-19 Market Scenario
14.14.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.15 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market Analysis
14.15.1 Pre-COVID-19 Market Scenario
14.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 LAMEA Market Size Estimation and Forecast
15.1 Market Outlook
15.2 LAMEA Market Size Estimation and Forecast
15.2.1 Pre-COVID-19 Market Scenario
15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.3 Country Market Size Estimation and Forecast
15.3.1 Pre-COVID-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 LAMEA Market Size Estimation and Forecast by Biopsy Method
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 LAMEA Market Size Estimation and Forecast by End-User
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 LAMEA Market Size Estimation and Forecast by Category
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 LAMEA Market Size Estimation and Forecast by Cancer Type
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 LAMEA Market Size Estimation and Forecast by Molecular Cancer Testing
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 LAMEA Market Size Estimation and Forecast by Cancer Imaging Test
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 Brazil Precision Cancer Diagnostic Test Market Analysis
15.10.1 Brazil is Making Significant Contributions to Cancer Research
15.10.2 Brazil Can Easily Become a Model for Other Latin American Countries, in Terms of the Potential Benefits of Precision Medicine
15.10.3 Pre-COVID-19 Market Scenario
15.10.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 South Africa Precision Cancer Diagnostic Test Market Analysis
15.11.1 To Develop Precision Medicine Requires More Specialised Professionals in South Africa
15.11.2 Pre-COVID-19 Market Scenario
15.11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 Saudi Arabia Precision Cancer Diagnostic Test Market Analysis
15.12.1 Precision Cancer Diagnostic Test Has Significantly Revolutionised the Cancer Diagnostic and Treatment Environment in Saudi Arabia
15.12.2 Pre-COVID-19 Market Scenario
15.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 Turkey Precision Cancer Diagnostic Test Market Analysis
15.13.1 Pre-COVID-19 Market Scenario
15.13.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 UAE Precision Cancer Diagnostic Test Market Analysis
15.14.1 Companies in the UAE Utilising New Collaboration Strategies to Increase Precision Cancer Diagnostic Test
15.14.2 Pre-COVID-19 Market Scenario
15.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 Rest of LAMEA Precision Cancer Diagnostic Test Market Analysis
15.15.1 Pre-COVID-19 Market Scenario
15.15.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Company Profiles
16.1 Bio-Rad Laboratories Inc.
16.1.1 Company Snapshot
16.1.2 Company Overview
16.1.3 Company Financial Profile
16.1.4 Company Product Benchmarking
16.1.5 Company Recent Developments
16.2 Illumina Inc
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Company Financial Profile
16.2.4 Company Product Benchmarking
16.2.5 Company Recent Developments
16.3 Biocept Inc.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Company Financial Profile
16.3.4 Company Product Benchmarking
16.3.5 Company Recent Developments
16.4 Epigenomics AG
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Company Financial Profile
16.4.4 Company Product Benchmarking
16.5 AstraZeneca plc
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Company Financial Profile
16.5.4 Company Product Benchmarking
16.5.5 Company Recent Developments
16.6 Myriad Genetics Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Company Product Benchmarking
16.6.4 Company Recent Developments
16.7 Quest Diagnostics Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Company Financial Profile
16.7.4 Company Product Benchmarking
16.7.5 Company Recent Developments
16.8 Abbott Laboratories
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Company Financial Profile
16.8.4 Company Product Benchmarking
16.8.5 Company Recent Developments
16.9 Agilent Technologies Inc.
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Company Financial Profile
16.9.4 Company Product Benchmarking
16.9.5 Company Recent Developments
16.10 Becton Dickinson and Co.
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Company Financial Profile
16.10.4 Company Product Benchmarking
16.10.5 Company Recent Developments
17 Conclusion and Recommendations
17.1 Conclusion Summary
17.2 Recommendations
List of Figures
Figure 1 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%))
Figure 2 Global Precision Cancer Diagnostic Test Market Segmentation
Figure 3 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%))
Figure 4 SWOT Analysis
Figure 5 PEST Analysis
Figure 6 Porters Five Forces
Figure 7 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%))
Figure 8 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 9 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 10 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 11 Global Precision Cancer Diagnostic Test Market Forecast, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 12 Global Precision Cancer Diagnostic Test Market Share Forecast by Region 2022, 2027, 2032 (%)
Figure 13 Global Precision Cancer Diagnostic Test Market by Region, 2022-2032 (USD Mn, AGR (%))
Figure 14 Global Precision Cancer Diagnostic Test Market by Region, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 15 Global Precision Cancer Diagnostic Test Market by Region, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 16 Global Precision Cancer Diagnostic Test Market by Region, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 17 Global Precision Cancer Diagnostic Test Market by Region, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 18 Global Precision Cancer Diagnostic Test Market Share Forecast by Biopsy Method 2022, 2027, 2032 (%)
Figure 19 Global Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%))
Figure 20 Global Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 21 Global Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 22 Global Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 23 Global Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 24 Global Precision Cancer Diagnostic Test Market Share Forecast by End-User 2022, 2027, 2032 (%)
Figure 25 Global Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%))
Figure 26 Global Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 27 Global Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 28 Global Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 29 Global Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 30 Global Precision Cancer Diagnostic Test Market Share Forecast by Category 2022, 2027, 2032 (%)
Figure 31 Global Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%))
Figure 32 Global Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 33 Global Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 34 Global Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 35 Global Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 36 Global Precision Cancer Diagnostic Test Market Share Forecast by Cancer Type 2022, 2027, 2032 (%)
Figure 37 Global Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%))
Figure 38 Global Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 39 Global Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 40 Global Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 41 Global Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 42 Global Precision Cancer Diagnostic Test Market Share Forecast by Molecular Cancer Testing 2022, 2027, 2032 (%)
Figure 43 Global Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%))
Figure 44 Global Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 45 Global Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 46 Global Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 47 Global Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 48 Global Precision Cancer Diagnostic Test Market Share Forecast by Cancer Imaging Test 2022, 2027, 2032 (%)
Figure 49 Global Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%))
Figure 50 Global Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 51 Global Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 52 Global Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 53 Global Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 54 North America Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 55 North America Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 56 North America Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 57 North America Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 58 North America Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 59 North America Precision Cancer Diagnostic Test Market by Country,2022-2032 (USD Mn, AGR(%))
Figure 60 North America Precision Cancer Diagnostic Test Market by Country,2022-2032 (USD Mn, AGR(%)) (V-Shaped Recovery Scenario)
Figure 61 North America Precision Cancer Diagnostic Test Market by Country,2022-2032 (USD Mn, AGR(%)) (W-Shaped Recovery Scenario)
Figure 62 North America Precision Cancer Diagnostic Test Market by Country,2022-2032 (USD Mn, AGR(%)) (U-Shaped Recovery Scenario)
Figure 63 North America Precision Cancer Diagnostic Test Market by Country,2022-2032 (USD Mn, AGR(%)) (L-Shaped Recovery Scenario)
Figure 64 North America Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%))
Figure 65 North America Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 66 North America Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 67 North America Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 68 North America Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 69 North America Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%))
Figure 70 North America Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 71 North America Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 72 North America Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 73 North America Precision Cancer Diagnostic Test Market by End-User, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 74 North America Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%))
Figure 75 North America Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 76 North America Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 77 North America Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 78 North America Precision Cancer Diagnostic Test Market by Category, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 79 North America Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%))
Figure 80 North America Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 81 North America Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 82 North America Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 83 North America Precision Cancer Diagnostic Test Market by Cancer Type, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 84 North America Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%))
Figure 85 North America Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 86 North America Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 87 North America Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 88 North America Precision Cancer Diagnostic Test Market by Molecular Cancer Testing, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 89 North America Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%))
Figure 90 North America Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 91 North America Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 92 North America Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 93 North America Precision Cancer Diagnostic Test Market by Cancer Imaging Test, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 94 US Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 95 US Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 96 US Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 97 US Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 98 US Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 99 Canada Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 100 Canada Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 101 Canada Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 102 Canada Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 103 Canada Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 104 Mexico Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 105 Mexico Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 106 Mexico Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 107 Mexico Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 108 Mexico Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 109 Europe Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%))
Figure 110 Europe Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 111 Europe Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 112 Europe Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 113 Europe Precision Cancer Diagnostic Test Market by Value, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 114 Europe Precision Cancer Diagnostic Test Market by Country, 2022-2032 (USD Mn, AGR (%))
Figure 115 Europe Precision Cancer Diagnostic Test Market by Country, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 116 Europe Precision Cancer Diagnostic Test Market by Country, 2022-2032 (USD Mn, AGR (%)) (W-Shaped Recovery Scenario)
Figure 117 Europe Precision Cancer Diagnostic Test Market by Country, 2022-2032 (USD Mn, AGR (%)) (U-Shaped Recovery Scenario)
Figure 118 Europe Precision Cancer Diagnostic Test Market by Country, 2022-2032 (USD Mn, AGR (%)) (L-Shaped Recovery Scenario)
Figure 119 Europe Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%))
Figure 120 Europe Precision Cancer Diagnostic Test Market by Biopsy Method, 2022-2032 (USD Mn, AGR (%)) (V-Shaped Recovery Scenario)
Figure 121 Europe
